Schizophrenia Treatment Adherence Investigation (STAI)

Janssen (J&J Innovative Medicine)

Status: Completed

Conditions: Schizophrenia; Schizoaffective Disorder

Treatments: Other: Risk status for medication adherence

Study type: Observational

Funder types: Industry

Identifiers

NCT01001481

CR013822

Details and patient eligibility

About

The primary objective of this treatment review and feedback program is to quantify the risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia.

Full description

The primary objective of this treatment review and feedback program is to quantify the risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia. Observational study - no study drug administered

Enrollment: 550 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of schizophrenia or schizoaffective disorder according to DSM-IV
• Currently treated in an outpatient clinic
• Able to provide informed consent
• Concurrent enrolment in clinical trials is acceptable
• Have completed all questions on the Drug Attitude Inventory (DAI-10) and Medication Adherence Rating Scale (MARS) survey

Exclusion criteria

• N/A

Trial design

550 participants in 1 patient group

001

Treatment:

Other: Risk status for medication adherence